Swiss earnings calls, October 2026: Galderma and Schindler raise 2026 guidance
Galderma said it raised its 2026 net sales growth guidance to 22.5%–23.5% at constant currency, from 19%–21%. Schindler raised its 2026 margin guidance for earnings before interest and taxes to 13.5% from 13%.
- 22.5%–23.5%
- Galderma, net sales growth guidance, fiscal year 2026, at constant currency
- 13.5%
- Schindler, margin guidance for earnings before interest and taxes, fiscal year 2026
- CHF 2.2 billion to CHF 3 billion
- Roche, divarasip peak-sales potential